This article is more than 5 years old. Information may no longer be current.
Long-term use of CGM in infants, toddlers possible
New data suggest that continuous glucose monitoring in children with type 1 diabetes who are younger than 4 years provided the ability to document glycemic control during a 6-month study period. Parents also self-reported a sense of safety knowing that they would be alerted to hypoglycemic episodes.
Researchers monitored the safety and efficacy of two continuous glucose monitoring (CGM) devices (Freestyle Navigator, Abbott; Paradigm, Medtronic) in 15 boys and eight girls with type 1 diabetes (mean age, 3 years; mean HbA1c, 8%). At baseline, 10 were using an insulin pump and 13 were receiving multiple daily injections.
At 6 months, follow-up data were available for 20 children. Among them, more than 40% were using CGM on a near-daily basis. During the final month of the study, nine used CGM at least 6 days per week; four used CGM 3 to 5 days per week; and seven used CGM fewer than 3 days per week.
According to results collected from the devices, hyperglycemia was usually present for more than half of the day; biochemical hypoglycemia rarely occurred. Participants experienced no severe skin reactions. HbA1c, however, did not change from baseline after 6 months of CGM use.
For more information:
- Tsalikian E. 1219-P. Presented at: American Diabetes Association’s 71st Scientific Sessions; June 24-28, 2011; San Diego.
Disclosure: The researchers report no relevant financial disclosures.